Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Recruiting

Phase 1

Phase 2

Seleno-L Methionine (SLM)-Axitinib-PembrolizumabSeleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Sponsor:

Mohammed Milhem

Code:

NCT05363631

Conditions

Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma Metastatic

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Selenomethionine (SLM)

Axitinib

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Mohammed Milhem on 2025-03-25.